CinderBio produces heat and acid-stable HTA-enzymes for proteomics and industrial applications, which are made from microbes that thrive in volcanic waters, allowing for faster workflow turnaround times and unique protein access.

CinderBio

Novotyme offers services to facilitate the transition to cloud computing while ensuring compliance with regulatory requirements and data security.

Novotyme

CinderBio | 861 followers on LinkedIn. Harnessing three billion years of biology for proteomics and industry | CinderBio produces extreme enzymes for proteomics and industry using proprietary technologies developed through ten years of research in Berkeley, California. Industrial enzymes are a growing, multi-billion dollar green industry that reduces energy, water, and harsh chemical use while improving process efficiency in many sectors. Despite the broad use and success of industrial enzymes, their application and economic impact has been severely limited by narrow thermal and chemical stability.

Chief Operating Officer at Newlight Technologies, Inc.

Mike Giardello

CEO at CinderBio

Steven Yannone

Bioprocess Engineer, Fermentation and Biochemistry at Cinder Biological

Parker Brand

Senior Research Associate at CinderBio

Allison Narlock

Difficult protein to analyze? See what our early #proteomics adopter says about CinderBio’s volcanic enzymes for difficult proteins... "I've tried all six standard enzymes in the lab and achieved only 24% coverage with a combined search. However, CinderBio enzymes enabled me to reach a remarkable 40% coverage for my challenging 160 kDa transmembrane target protein. The combined search using both standard and CinderBio enzymes resulted in an impressive 64% coverage.” - Early biotech adopter Interested in getting results like theirs? Visit CinderBio.com or ask us on LinkedIn or at info@cinderbio.com about other advantages for proteomics. #Proteomics #TeamMassSpec #LCMS

See what our early #proteomics adopters Albert J. R. Heck and an HHMI researcher are saying about CinderBio’s volcanic enzymes for de novo sequencing... “There is a growing need for stable and robust proteases to help us to make advances in proteomics, especially for the fast growing areas of top-down proteomics and de novo sequencing. Working with CinderBio we have explored such enzymes that gave us unprecedented (100%) sequence coverage with one enzyme, helping us to achieve our aims to de novo sequence antibodies.” - Professor Albert J. R. Heck, Utrecht University ‘‘…with still limited number of experimental runs Krakatoa looks outstanding in de novo sequencing, as in number of unique peptides and achieved coverage per run. Best in show.” - HHMI researcher Interested in getting results like theirs? Visit CinderBio.com or ask us on LinkedIn or at info@cinderbio.com about other advantages for proteomics. #HUPO2024 #LCMS #Proteomics #TeamMassSpec Albert Heck Bioinformatics Solutions Inc. Abterra Biosciences Rapid Novor Creative Biolabs Biomatik Corporation Absolute Antibody

Can’t see your proteomics target protein, PTM, or target sequence? Have you tried CinderBio’s volcanic proteases? They can provide significant additional sequence coverage and hundreds of ID’s not seen with trypsin. Expand your proteomics capabilities with fast and simple sample prep that delivers what trypsin cannot. You might find you targets here ( https://lnkd.in/gkQTbhEv ) on page 10 #proteomics #biomarkers #teammassspec

TL;DR version: Krakatoa users need less time and 50% fewer proteases for #denovosequencing of #antibodies . Potential for improvements in #biologics characterization as well. Promotional pricing of Krakatoa ending soon click here to buy https://c-bio.link/s2wyjc or send a PO to sales at cinderbio.com . #Proteomics #MassSpec #TeamMassSpec #mAbs #biosimilars #pharma #biotech Original post: https://lnkd.in/gYxa-nNB

We want to update you on an exciting application of HTA-Proteases. Krakatoa users performing #denovosequencing of #antibodies have reported saving significant time and money by reducing the number of proteases required to achieve sufficient breadth and depth of coverage and get confident results. See an example below of using our Krakatoa protease in this application. If you’re interested in learning more, click here https://c-bio.link/z3btzd . In addition to de novo sequencing, the CinderBio team presented a poster at ASMS titled "Blood to Biomarker Quantitation in Under One Hour with Rapid Proteomics using a Hyperthermoacidic Protease”. We report how using quick single-step sample preparation of Krakatoa with high throughput dual trapping column achieves “Rapid Proteomics” with unprecedented turnaround for clinical proteomics (< 1 hour). We found a systematic evaluation of this methodology reproducibly quantified over 160 proteins from just 1 microliter of whole blood. Furthermore, HTA-Protease reaction conditions stabilize Angiotensin I and II peptides permitting detection and quantitation of these bio-active peptides in under half an hour. A pre-print of the work is available here: https://c-bio.link/ggrrs1 . Lastly, based on feedback from all of you, we have revised our suggested protocols for using Krakatoa and Vesuvius. Click here to download ( https://c-bio.link/wrba4z ). Highlights include: Enzyme Dose · Change of suggested Krakatoa dose to a range from 0.2U – 2.0U / ug (note that 1 U = 8 nanograms of enzyme). Lower doses require longer digestion times. 2.0 U / ug was used in the above “Blood to Biomarker” work to achieve digestion times of 20 minutes. · Change of suggested Vesuvius dose to a range from 0.6U – 6.0U / ug (note that 1 U = 8 nanograms of enzyme). This is a substantial change from the previous guidance. Searches · A reminder, alkylation is not required because at pH 3.0 during digestion Cysteines will remain protonated. If you do alkylate anyway, please make carbamidomethylation a variable modification. That’s it. If you’re interested in learning more and improving your work flow, take advantage of our current promotional pricing. Please share your questions on the use of these amazing enzymes to help us improve our service to you, our customers, and to better serve the larger scientific community. Have an interesting application for HTA-Proteases? We are currently engaging in collaborative studies, “Contact Us” using the form on our website or here on LinkedIn. Best, The CinderBio team #proteomics #TeamMassSpec #denovosequencing

Our poster, "Blood to biomarker quantitation in under one hour..." was a hit at #ASMS2024 . If you missed it, or want to learn more the Biorxiv preprint is here: https://c-bio.link/ohkzal A big thank you to Simion Kreimer for all his work. #Proteomics #TeamMassSpec

Team CinderBio with Simion Kreimer of the Jennifer Van Eyk, PhD group (Cedars-Sinai) ready to present our collaborative work at #ASMS2024 . Come see our breakthrough work on "Blood to Biomarkers in under one hour..." at Poster WP-189 Wednesday. Preprint on Biorxiv ( https://lnkd.in/dAEmYRxR ) #Proteomics #TeamMassSpec

Dealing with challenging proteins? Coming to #ASMS2024 ? Visit with CinderBio there! There will be two posters with fascinating insight into the use of our alternative proteases for #Proteomics . Interested in meeting during the conference? Please use this link ( https://lnkd.in/gsdPZHBb ) or use the contact us form on our webpage ( https://lnkd.in/gd8fSTWk ) to setup an appointment. #TeamMassSpec #massspec

CinderBio will see you at #ASMS2024 ! There will be two posters with fascinating insight into the use of our alternative proteases for #Proteomics . They are: TP 342 on Tuesday, 6/4: Rapid Semi-automated Enzyme Profiling WP 189 on Wednesday 6/5: Near Real-Time Monitoring of Blood Biomarkers with “Rapid Proteomics” Interested in meeting during the conference? Please use this link ( https://lnkd.in/gsdPZHBb ) or use the contact us form on our webpage ( https://lnkd.in/gd8fSTWk ) to setup an appointment. #TeamMassSpec #massspec

Metric
Company Name	CinderBio	Novotyme
Symbol
MSH ID	COM:CINDERBIO	COM:NOVOTYME
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Technology
Industry	Biotechnology	Information Technology & Services
Country	US	DE
Stage	Grant
Employee Count
Website	cinderbio.com	novotyme.com
LinkedIn	cinderbio	novotyme
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital	1.65M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CIND

COM:CINDERBIO

CinderBio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue